Squarepoint Ops LLC Reduces Position in United Therapeutics Corporation $UTHR
by Teresa Graham · The Cerbat GemSquarepoint Ops LLC reduced its position in shares of United Therapeutics Corporation (NASDAQ:UTHR – Free Report) by 38.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 8,351 shares of the biotechnology company’s stock after selling 5,145 shares during the period. Squarepoint Ops LLC’s holdings in United Therapeutics were worth $2,400,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Chung Wu Investment Group LLC purchased a new position in United Therapeutics in the second quarter valued at $29,000. WealthCollab LLC lifted its holdings in United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 38 shares during the last quarter. Rakuten Securities Inc. boosted its position in shares of United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 46 shares in the last quarter. SVB Wealth LLC purchased a new position in shares of United Therapeutics in the 1st quarter valued at about $32,000. Finally, Geneos Wealth Management Inc. raised its position in shares of United Therapeutics by 141.7% during the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 85 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.
Insider Transactions at United Therapeutics
In other United Therapeutics news, COO Michael Benkowitz sold 22,500 shares of the stock in a transaction that occurred on Monday, September 22nd. The stock was sold at an average price of $416.35, for a total transaction of $9,367,875.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last 90 days, insiders sold 624,054 shares of company stock valued at $283,834,364. Insiders own 10.30% of the company’s stock.
United Therapeutics Price Performance
UTHR stock opened at $510.94 on Thursday. The company has a market cap of $22.00 billion, a price-to-earnings ratio of 19.36, a price-to-earnings-growth ratio of 4.96 and a beta of 0.86. The company has a fifty day moving average price of $460.85 and a 200 day moving average price of $378.34. United Therapeutics Corporation has a 12 month low of $266.98 and a 12 month high of $513.93.
United Therapeutics (NASDAQ:UTHR – Get Free Report) last posted its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, beating analysts’ consensus estimates of $6.89 by $0.27. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The company had revenue of $799.50 million for the quarter, compared to analyst estimates of $812.87 million. During the same period in the previous year, the business posted $6.39 earnings per share. United Therapeutics’s quarterly revenue was up 6.8% on a year-over-year basis. As a group, analysts anticipate that United Therapeutics Corporation will post 24.48 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of brokerages recently issued reports on UTHR. Oppenheimer upped their price target on United Therapeutics from $510.00 to $575.00 and gave the company an “outperform” rating in a report on Friday, September 5th. Wells Fargo & Company raised their price objective on shares of United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a report on Thursday, October 30th. Jefferies Financial Group restated a “buy” rating and issued a $575.00 target price on shares of United Therapeutics in a report on Wednesday, November 19th. UBS Group lifted their price target on shares of United Therapeutics from $580.00 to $600.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. Finally, Weiss Ratings restated a “buy (b-)” rating on shares of United Therapeutics in a research note on Monday, December 8th. Eight equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $505.00.
Read Our Latest Report on United Therapeutics
About United Therapeutics
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Featured Articles
- Five stocks we like better than United Therapeutics
- What is the Australian Securities Exchange (ASX)
- Post 35% Surge, Analysts Eye More Upside in Copper Giant Freeport
- What Are Growth Stocks and Investing in Them
- Why a SpaceX IPO Could Be a Major Catalyst for GOOGL Stock
- Stock Market Upgrades: What Are They?
- Can Upwork Maintain Its Comeback? Reasons to Be Bullish and Bearish
Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR – Free Report).